
Linagliptin is a prescription medication primarily used to manage blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs known as DPP-4 inhibitors, which work by increasing the levels of incretin hormones in the body. These hormones help regulate insulin secretion and decrease the amount of glucose produced by the liver, leading to improved glycemic control.
USD $37.45
Trajenta (Linagliptin): Comprehensive Guide
Trajenta is an oral medication indicated for the management of Type 2 diabetes mellitus. It contains the active ingredient linagliptin, which belongs to the class of drugs known as DPP-4 (Dipeptidyl Peptidase-4) inhibitors. Trajenta works by inhibiting the DPP-4 enzyme, thereby prolonging the action of incretin hormones such as GLP-1. This results in increased insulin secretion and decreased glucagon production in a glucose-dependent manner, ultimately helping to lower blood sugar levels.
Manufactured by Boehringer Ingelheim, Trajenta is Clinically Approved Pharmaceuticals and is used either as monotherapy or in combination with other antidiabetic agents to provide effective glycemic control.
References: FDA Trajenta Prescribing Information, Drugs.com: Linagliptin
Clinical studies have demonstrated that Trajenta significantly lowers HbA1c levels in patients with Type 2 diabetes. Its glucose-dependent mechanism ensures that insulin secretion is enhanced only when needed, reducing the risk of hypoglycemia.
Reference: FDA Trajenta Prescribing Information
Trajenta is known to be weight neutral. Unlike some other antidiabetic medications that contribute to weight gain, linagliptin does not significantly affect body weight, making it a favorable option for patients concerned about weight management.
Due to its mode of action, Trajenta has a low intrinsic risk of causing hypoglycemia when used as monotherapy. This safety feature is particularly beneficial when managing blood sugar levels in a controlled manner.
The CAROLINA trial has established the cardiovascular safety of linagliptin. This landmark study confirmed that Trajenta does not increase cardiovascular risk in patients with Type 2 diabetes, making it a reliable option for long-term management.
Reference: Linagliptin Safety Profile on PubMed
Reference: American Diabetes Association (ADA)
Trajenta is prescribed to:
Trajenta works by inhibiting the DPP-4 enzyme, which is responsible for breaking down incretin hormones. By preventing this breakdown, the levels of incretin hormones such as GLP-1 remain elevated, leading to:
This dual effect helps to stabilize blood sugar levels in a glucose-dependent manner, thereby reducing the risk of hypoglycemia.
| Strength | Recommended Use |
|---|---|
| 5 mg | Standard once-daily dose for adults with Type 2 diabetes |
To ensure authenticity and safety, purchase Trajenta from reputable online pharmacies such as Waldrugmart. Licensed pharmacies require a valid prescription, offer verified customer support, and provide secure shipping options.
For additional details on dosing and administration:
Trajenta (Linagliptin) is an effective, Clinically Approved Pharmaceuticals DPP-4 inhibitor that offers reliable glycemic control with a low risk of hypoglycemia. Its weight-neutral profile and lack of need for dose adjustments in renal or hepatic impairment make it an excellent choice for a wide range of patients with Type 2 diabetes. Backed by robust clinical data and supported by trials such as the CAROLINA trial, Trajenta provides a convenient and safe option for long-term diabetes management. Always consult with your healthcare provider to determine if Trajenta is right for your treatment plan.
Disclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before starting or modifying any treatment regimen.